InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pharmaceutical stocks have been on the rebound and many are raising their prices this year. What does that mean...
These pot stocks all lost at least half of their value.
By Nate Raymond BOSTON (Reuters) - The former chief executive of Insys Therapeutics Inc (O:INSY) has agreed to plead guilty to participating in a scheme to bribe doctors to...
INSYS Therapeutics, Inc. (NASDAQ:INSY) announced positive results from its dose-finding pharmacokinetic ("PK") study —INS015-18-124—evaluating proprietary formulation...
Legalization of cannabis has been at the forefront of the news as both a social and medical issue for the past few years. The issues are complex, and many countries have held...
INSYS Therapeutics, Inc. (NASDAQ:INSY) announced that an FDA advisory committee voted against the approval of its lead pipeline candidate, buprenorphine sublingual spray, for the...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Sell||Sell||Sell||Strong Sell||Strong Sell|
|Technical Indicators||Sell||Strong Buy||Sell||Sell||Strong Sell|
|Summary||Sell||Neutral||Sell||Strong Sell||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Belt Hold Bearish||30||Current|
|Engulfing Bearish||15||1||Jan 16, 2019 03:30PM|
|Downside Gap Three Methods||1W||2||Dec 30, 2018|
|Three Outside Down||30||2||Jan 16, 2019 02:30PM|
|Petroleo Brasileiro Petrobras ADR||15.30||15.35||15.01||+0.06||+0.39%||14.21M||16/01|
|Bank of America||28.45||28.72||27.86||+1.90||+7.16%||163.13M||16/01|
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.Read More
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|U.S. Commodity Futures Trading Commission (United States)||$250||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.